Literature DB >> 11757749

Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice.

S Homma1, G Toda, J Gong, D Kufe, T Ohno.   

Abstract

BACKGROUND: The prevention of recurrence of hepatocellular carcinoma (HCC) after treatment is very important for improvement of the prognosis of HCC patients. Dendritic cells (DCs) are potent antigen-presenting cells that can prime naive T cells to induce a primary immune response. We attempted to induce preventive antitumor immunity against HCC by immunizing BALB/c mice with fusions of DCs and HCC cells.
METHODS: Murine bone marrow-derived DCs and a murine HCC cell line. BNL cells, were fused by treatment with 50% polyethyleneglvcol (PEG). Fusion efficacy was assessed by the analysis of fusions of BNL cells stained with red fluorescent dye and DCs stained with green fluorescent dye. Mice injected intravenously with DC/BNL fusions were challenged by BNL cell inoculation.
RESULTS: About 30% of the PEG-treated non-adherent cells with both fluorescences were considered to be fusion cells. The cell fraction of DC/BNL fusions showed phenotypes of DCs, MHC class II, CD80, CD86, and intercellular adhesion molecule (ICAM)-1, which were not expressed on BNL cells. Mice immunized with the fusions were protected against the inoculation of BNL tumor cells, whereas injection with a mixture of DCs and BNL cells not treated with PEG did not provide significant resistance against BNL cell inoculation. Splenocytes from DC/BNL fusion-immunized mice showed lytic activity against BNL cells.
CONCLUSIONS: These results demonstrate that immunization with fusions of DCs and HCC cells is capable of inducing preventive antitumor immunity against HCC.

Entities:  

Mesh:

Year:  2001        PMID: 11757749     DOI: 10.1007/s005350170019

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  16 in total

1.  Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo.

Authors:  Jin-Kun Zhang; Jun Li; Juan Zhang; Hai-Bin Chen; Su-Biao Chen
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

Review 2.  Cancer vaccine by fusions of dendritic and cancer cells.

Authors:  Shigeo Koido; Eiichi Hara; Sadamu Homma; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2010-02-18

3.  Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.

Authors:  Sadamu Homma; Hideo Komita; Yukiko Sagawa; Tsuneya Ohno; Gotaro Toda
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

4.  Tumor vaccine against recurrence of hepatocellular carcinoma.

Authors:  Bao-Gang Peng; Li-Jiang Liang; Qiang He; Ming Kuang; Jia-Ming Lia; Ming-De Lu; Jie-Fu Huang
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

5.  A novel, rapid strategy to form dendritomas from human dendritic cells and hepatocellular carcinoma cell line HCCLM3 cells using mature dendritic cells derived from human peripheral blood CD14+ monocytes within 48 hours of in vitro culture.

Authors:  Xin Guan; Ji-Run Peng; Lan Yuan; Hui Wang; Yu-Hua Wei; Xi-Sheng Leng
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

6.  Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.

Authors:  Shigeo Koido; Sadamu Homma; Eiichi Hara; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2010-04-07

7.  Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.

Authors:  S Homma; Y Sagawa; M Ito; T Ohno; G Toda
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

8.  Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine.

Authors:  Toshio Iinuma; Sadamu Homma; Tetsuo Noda; Donald Kufe; Tsuneya Ohno; Gotaro Toda
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

9.  In vitro antitumor immune response induced by fusion of dendritic cells and colon cancer cells.

Authors:  Feng Xu; Ying-Jiang Ye; Shan Wang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

10.  Lymphotactin enhances the in-vitro immune efficacy of dendritoma formed by dendritic cells and mouse hepatocellular carcinoma cells.

Authors:  Hao Zhang; Guo-ping Jiang; Shu-sen Zheng; Li-hua Wu; Feng Zhu; Zhen-lin Yang
Journal:  J Zhejiang Univ Sci       Date:  2004-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.